The Whiplash Generation: How America Learned to Quit One Vice and Embrace Another

On 7 May 2026, Adam Carolla made a point on Megyn Kelly's program that landed with unusual force in the comment sections of X. The observation was simple: the United States spent decades waging an aggressive public health campaign against cigarette smoking, succeeded in dramatically reducing smoking rates, and then pivoted—without obvious apology—to treating cannabis as harmless medicine. The whiplash, Carolla suggested, was not subtle.

The remark resonated because it named something many Americans sense but rarely hear articulated in mainstream media. The anti-smoking crusade of the late twentieth century was one of the most successful public health interventions in American history. Cigarette consumption per capita peaked in the early 1960s and has declined steadily since. The 1964 Surgeon General's report, the subsequent warning labels, the ban on tobacco advertising on broadcast television, the cigarette tax regimes adopted state by state—these measures were framed as existential necessities. Smoking was not merely a bad habit; it was a public health crisis requiring a coordinated government response. The language was absolute. There were no asterisks, no harm-reduction caveats, no serious public debate about whether occasional smoking carried acceptable risks.

That campaign succeeded. By 2024, roughly 11 percent of American adults smoked, down from roughly 42 percent in 1965. Lives were demonstrably saved. The reduction in lung cancer rates, cardiovascular disease, and chronic respiratory illness among former smokers constitutes one of the clearest evidence bases in preventive medicine.

What Carolla identified is the way the same institutional machinery—the medical establishment, the regulatory agencies, the public health communications apparatus—has now largely pivoted to normalizing a substance that was, within living memory, classified alongside heroin as a Schedule I controlled substance with no accepted medical use and high abuse potential. The contradiction is not merely rhetorical. It goes to the question of what public health authority is actually for, and whether its recommendations track evidence or convenience.

The Evidence Gap Nobody Wants to Measure

The scientific literature on cannabis is, by most assessments, thinner than the evidence base that underpinned anti-smoking campaigns. Marijuana research has been constrained for decades by the Drug Enforcement Administration's classification, which made large-scale clinical trials difficult to conduct. What exists suggests that cannabis carries real risks: impaired adolescent brain development, elevated psychosis risk in predisposed populations, dependence liability, and respiratory harm when smoked. The National Academies of Sciences, Engineering, and Medicine published a comprehensive review in 2017 that found "substantial evidence" linking cannabis use to impaired driving, "moderate evidence" of a link to reduced academic achievement, and "limited evidence" of therapeutic benefit for specific conditions—chiefly chronic pain and muscle spasticity.

None of this is equivalent to the catastrophic harm profile of tobacco. But it also does not support the framing that cannabis is categorically harmless. The disconnect between what research supports and what public health messaging has normalized is the space Carolla's observation occupies.

The pharmaceuticalization of cannabis—its rebrand as a medicine through the proliferation of dispensaries, medical marijuana cards, and state-level legalization frameworks—has proceeded faster than the evidence base has been allowed to develop. State regulators in California, Colorado, and Oregon have found that product testing is underfunded and inconsistent. The potency of modern cannabis products, particularly concentrates, is significantly higher than what was available in previous decades. Public health officials in several states have noted a rise in cannabis-related emergency department visits concurrent with legalization.

The counterargument, advanced by legalization advocates and some medical researchers, is that prohibition itself carries harms—arrest and incarceration rates that disproportionately affect minority communities, an unregulated market with no quality controls, and the opportunity cost of denying patients access to a substance with genuine therapeutic applications. This is not a trivial argument. The racial disparities in marijuana enforcement were documented extensively and contributed meaningfully to the political coalition that passed state-level legalization measures.

But that argument addresses the failures of prohibition, not the merits of unrestricted normalization. A third option—rescheduling, allowing medical use, maintaining some regulatory framework while restricting recreational commercialization—gets little traction in either the pro-legalization or the anti-legalization camp, which suggests the debate is less about evidence than about ideology.

The Communications Apparatus and Its Convenient Memory

What Carolla's observation exposes, perhaps unintentionally, is the degree to which public health messaging is a political artifact. The anti-smoking campaign was not driven by pure science either—it was driven by a political coalition that included a White House committed to the effort, a tobacco industry that had overplayed its hand so badly that even sympathetic lawmakers abandoned it, and a media environment willing to treat cigarettes as a genuine crisis.

The normalization of cannabis has followed a different political arc. It was driven, in significant part, by the financial interests of a nascent legal industry, the advocacy infrastructure built around criminal justice reform, and a cultural moment in which anything associated with the counterculture of the 1960s and 1970s was due for rehabilitation. These are not illegitimate motivations—but they are political ones, and treating them as purely scientific obscures how policy actually gets made.

The health communication research on this question is not flattering to either side. Studies have found that both anti-smoking messaging and pro-cannabis messaging tend to overstate their respective cases. The anti-smoking campaign was effective partly because it treated cigarettes as uniquely dangerous, a framing that sometimes oversimplified the relative risk calculus. The cannabis normalization movement has, in places, gone to the opposite extreme—treating the substance as so benign that any concern is dismissible as reefer madness.

The result is a public that receives contradictory signals from institutions it is supposed to trust. When the CDC, the NIH, and the Surgeon General speak with one voice on one substance and then go largely silent—or actively contradict themselves—on another, the erosion of institutional credibility is not a side effect. It is a predictable outcome.

Generational Division and the Cost of Silence

The generation that grew up with anti-smoking ads, with "Just Say No," with D.A.R.E. programs, and with the unambiguous message that drugs are bad and the government will tell you so, is now watching those same institutions tell them that a substance once lumped with cocaine and heroin is now medicine. The cognitive dissonance is real, and it has political consequences.

That generation's children—the ones who came of age in states where dispensaries outnumber Starbucks—have a different baseline. For them, cannabis normalization is simply the water they swim in. The whiplash Carolla identified is generational: it is most acute for people who remember the before and the after, and least perceptible to those for whom the after is all there is.

What gets lost in the culture-war framing is that the underlying question is tractable. Better research is possible. A regulatory framework that distinguishes between recreational commercialization and medical use is possible. Public health messaging that is honest about both the harms of cannabis and the harms of prohibition is possible. What currently exists is neither honest research nor honest messaging—it is a political settlement dressed as medicine.

The sources do not specify what Carolla's broader policy prescriptions would be, nor is there evidence that he was advancing a legislative agenda. His was a cultural observation, and it landed because it named a contradiction that the people receiving the messaging are experiencing in real time. When institutions lose the ability to hold a consistent line, they do not lose authority on the specific question at hand—they lose authority on every question thereafter.

That is the stakes of the whiplash, and it is not confined to cannabis.